CARSGEN-B

CARsgen Technology opened lower and continued to decline in the morning session, closing down 4.8% at HK$13.49 on turnover of 674,000 shares and HK$9.23 million. The stock opened at HK$14.14 at 09:30 BJ and immediately faced selling pressure, hitting an intraday low of HK$13.45 before failing to recover above the opening price. The weakness came as market enthusiasm cooled following the approval of its first-in-world solid-tumor CAR-T therapy, zevorcabtagene autoleucel, with the current pullback likely reflecting profit-taking after the initial rally. Recent corporate actions, including the issuance of 20 million shares via option exercise and a discretionary share buyback of up to 5% of capital, have failed to provide support. Financially, Q4 2025 revenue surged 136% year-over-year to HK$41.5 million, with net loss narrowing 94.8%, though the net profit margin remained negative at -30%, indicating early-stage commercialization. The stock now trades 52.8% below its 52-week high of HK$28.60 and below its 20-day moving average of HK$15.16, underscoring continued technical weakness.

CARsgen opened sharply lower in the morning session, initially at HKD 14.72 before quickly sliding to HKD 14.03 by 9:46 BJ, down approximately 5.0%, approaching the 52-week low of HKD 10.87. The sell-off was primarily driven by profit-taking pressure after the high price tag of its solid-tumor CAR-T therapy, Saizekai (zevorcabtagene autoleucel), following its approval as the world's first such therapy, compounded by recent downward revisions from several institutions. Despite Q4 revenue surging 136.01% YoY to HKD 41.53 million and net loss narrowing 94.76% YoY, the stock remains significantly below its 52-week high of HKD 28.6 (-50.98%) and trails both its 20-day moving average (HKD 15.19) and 60-day moving average (HKD 17.08), indicating substantial technical weakness. However, the company's gastric cancer consolidation trial has reported no recurrences to date, offering some long-term clinical support.

CARsgen opened lower and continued to decline, accelerating in the afternoon session to close at HKD 15.17, down 5.07% from the previous close of HKD 15.98, with an intraday range of 5.26%. The stock briefly opened at HKD 15.98 before sliding, hitting a morning low of HKD 15.33 and an intraday low of HKD 15.17 in the afternoon, on thin volume of 1.68 million shares and turnover of HKD 26.22 million. The sell-off likely reflects continued digestion of recent losses and a lack of fresh positive catalysts. Q4 2025 revenue surged 136.01% YoY to HKD 41.53 million, while net loss narrowed sharply by 94.76% YoY to HKD 12.44 million, yet the company remains unprofitable with a P/E of -83.2x and a high P/B of 10.39x. At HKD 15.17, the stock is down 0.98% YTD, 46.96% below its 52-week high of HKD 28.60, but still 39.56% above the 52-week low of HKD 10.87, and trading below the MA60 (HKD 17.856) while hovering near the MA20 (HKD 15.138). However, its product Saizezeng (zeverocabtagene autoleucel) remains the world's first approved CAR-T therapy for solid tumors, and earlier trial data for satri-cel in gastric cancer showed no recurrences, providing long-term promise.

CARsgen suffered a sharp intraday decline, dropping as low as HKD 14.72 in the morning session—a 13.8% plunge from the previous close—before recovering to close at HKD 15.96, down 6.6% for the day. The selloff was driven by concerns over the hefty price tag of its world-first solid-tumor CAR-T therapy, Satri-cel (zevorcabtagene autoleucel), after the drug's initial approval in China sparked investor skepticism about market adoption. The company's buyback plan of up to 5% of capital failed to fully stem the decline. Despite the pullback, the stock remains 44.2% below its 52-week high of HKD 28.6, though it trades above the 20-day moving average of HKD 15.14 and has gained 4.2% year-to-date. However, the company's negative P/E ratio of -87.5x underscores persistent valuation challenges for pre-profit biotech firms.

CARsgen Therapeutics surged 6.88% to close at HKD 17.08 on elevated turnover, recovering from a two-day selloff triggered by pricing concerns over its CAR-T therapy Satri-cel, as the company announced a discretionary share buyback plan of up to 5% of capital, reinforcing positive sentiment from the recent global-first approval for a solid tumor CAR-T therapy. The stock opened lower at HKD 15.72, rebounded to an intraday high of HKD 17.34 in the morning session, and traded in a narrow range in the afternoon, with a daily swing of 10.2%. Financially, Q4 revenue surged 136% YoY to HKD 41.5 million, while net loss narrowed 94.8% to HKD 12.4 million, though the stock trades at a PB of 11.7x and remains 6.1% below its 60-day moving average of HKD 18.196, 40.3% off its 52-week high of HKD 28.6. However, market skepticism persists regarding the pricing and commercial ramp of the first-in-class solid tumor CAR-T, leaving the stock's near-term trajectory uncertain.